What Happens to a Drug Market When the Cure Shows Up?
The first in-body CRISPR therapy just aced Phase 3: one infusion, 87% fewer attacks. Five companies built annuity businesses on treating this disease forever — and the repricing started before the FDA even votes.
On June 1, 2026, a Cambridge, Massachusetts biotech announced something no company had ever done before: it edited a gene inside living patients' bodies, in a Phase 3 trial, and won.
Intellia Therapeutics' lonvoguran ziclumeran — lonvo-z, because nobody has time for the full name — is a CRISPR-based therapy for hereditary angioedema (HAE), a rare genetic disease affecting roughly one in 50,000 people. HAE patients suffer unpredictable attacks of severe swelling in the face, limbs, gut, and — dangerously — the airway. Untreated laryngeal attacks kill. For decades, managing the disease has meant lifelong medication: infusions, injections, or daily pills to suppress attacks, plus rescue drugs for the breakthroughs.
Lonvo-z is different in kind, not degree. It is a single outpatient infusion. Lipid nanoparticles carry CRISPR machinery to the liver, where it permanently inactivates the KLKB1 gene — the source of the kallikrein protein that drives the swelling cascade. One appointment, and the gene that causes the disease stops working. Forever, as far as anyone can tell.
The Phase 3 HAELO results were not ambiguous. Patients receiving one 50 mg dose saw an 87% reduction in confirmed attacks versus placebo over the measurement window. Sixty-two percent were completely attack-free for six months — against 11% in the control group. Safety and tolerability were described as favorable. Intellia immediately began a rolling submission to the FDA and is targeting a US launch in the first half of 2027.
Why "in vivo" is the entire story
CRISPR already had its first approval. Casgevy, from Vertex and CRISPR Therapeutics, was cleared in late 2023 for sickle cell disease and beta-thalassemia. It works — the science is genuinely curative. Commercially, it has been a cautionary tale: a $2.2 million therapy that requires harvesting a patient's stem cells, editing them in a lab, and destroying the patient's remaining bone marrow with chemotherapy before reinfusion. Weeks of hospitalization, a handful of qualified treatment centers, and a launch measured in dozens of patients rather than thousands. The lesson investors took: gene editing cures diseases but not business models.
Lonvo-z breaks that frame. No cell harvesting, no chemotherapy, no transplant ward. It ships like a biologic and infuses like one, in a routine outpatient visit. If Casgevy proved CRISPR works, HAELO proved it can scale. That is why this readout matters far beyond one rare disease — it is the first demonstration that the deliverable, repeatable version of gene editing holds up in a pivotal trial.
The market it just landed on
Here is where it gets uncomfortable for everyone else. HAE therapeutics is a multibillion-dollar global market — roughly $3.5 billion in 2025 and, until June, projected to more than double by the early 2030s. It is also one of the most crowded rare-disease spaces in pharma: Takeda's injectable Takhzyro dominates long-term prophylaxis, BioCryst's oral Orladeyo has grown into a franchise worth hundreds of millions a year, KalVista won approval in 2025 for Ekterly, the first oral on-demand rescue drug, and CSL's Andembry and Ionis's Dawnzera both launched into prophylaxis within the last eighteen months.
Every one of those products shares a business model: the patient never stops paying. Prophylaxis regimens routinely cost six figures per patient per year, in some cases exceeding half a million dollars. Wall Street values these franchises as annuities — predictable, high-margin, decades long.
Lonvo-z proposes to end the annuity with one infusion. The question is no longer whether the science works. It is who gets repriced, in which order, and what the one-shot cure is actually worth.
The rest of this briefing is for paid members: the annuity-versus-cure pricing math and what lonvo-z can realistically charge, the exposure ranking across Takeda, BioCryst, KalVista, CSL, and Ionis, the ATTR program that is the real prize inside Intellia, and the catalyst calendar through launch.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.